MM-233 Evaluation of the Comparative Effectiveness of In-Class Transition (iCT) to All-Oral Ixazomib-Lenalidomide-Dexamethasone (IRd) After Bortezomib (V)-Based Induction Therapy vs Patients Who Continued to Receive Parenteral V-Based Therapy in Newly Diagnosed Multiple Myeloma (NDMM)

Suman Kambhampati, Robert Rifkin, Caitlin Costello, Ruemu Birhiray, Joshua Richter, Rafat Abonour, Hans Lee, Yong Jin Kim, Kaili Ren, Dawn Marie Stull, Dasha Cherepanov, Kimberly Bogard, Stephen Noga, Saulius Girnius

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'MM-233 Evaluation of the Comparative Effectiveness of In-Class Transition (iCT) to All-Oral Ixazomib-Lenalidomide-Dexamethasone (IRd) After Bortezomib (V)-Based Induction Therapy vs Patients Who Continued to Receive Parenteral V-Based Therapy in Newly Diagnosed Multiple Myeloma (NDMM)'. Together they form a unique fingerprint.

Medicine & Life Sciences